Image

Metformin Treatment in Progressive Multiple Sclerosis

Recruiting
30 - 65 years of age
Both
Phase N/A

Powered by AI

Overview

The purpose of this study is to assess the safety of metformin for treatment of progressive multiple sclerosis

Description

This will be a single site 1:1 randomized, placebo controlled trial of metformin treatment vs matching placebo in 44 men and women with primary progressive multiple sclerosis and secondary multiple sclerosis, without diabetes, not treated with metformin aged 30-65. The trial will last 12 months and have 3 study visits, baseline, 6 months, and 12 months. The trial will be preceded by a screening period. Over the initial 30 day titration period subjects will be titrated from 500 mg a day to 2,000 mg of metformin in increments of 500 mg every 10 days. Patients will remain on their tolerated dose and included in analysis on an intent to treat basis. Brain MRI, cognitive testing and clinical measures will be collected at baseline, month 6 and month 12. OCT will be collected at baseline and month 12. The primary outcomes are the following safety outcomes: 1) number of patients with adverse events 2) number of patients with laboratory abnormalities 3) number of patients with new T2 lesions on MRI. The secondary outcomes include reduction in localized cortical thinning on brain MRI; reduction in thalamic atrophy on brain MRI. Further exploratory outcomes include 1) improvement in SDMT-oral score, 2) improvement in CVLT-II score, 3) improvement in PACC score 4) improvement in PASAT score. Exploratory outcomes include 1) Decrease in plasma neurofilament light chain levels, 2) Reginal nerve fiber layer preservation on OCT, 3) Ganglion cell inner plexiform layer preservation, and 4) Percentage of phase rim lesions.

Eligibility

Inclusion Criteria:

  1. Patient signed informed consent.
  2. Age 30-65
  3. Primary Progressive Multiple Sclerosis or Secondary Progressive Multiple Sclerosis as defined by the 2017 McDonald Criteria
  4. Intent to maintain current MS disease modifying treatment through the trial duration

Exclusion Criteria:

  1. Clinical relapse in prior 12 months
  2. New T2 lesion or gadolinium enhancing lesion in prior 12 months
  3. Glucocorticoid use in prior six months outside the context of premedication for disease modifying treatment
  4. Changes in disease modifying therapy in prior three months
  5. Plans to change current disease modifying therapy
  6. Contraindication to MRI, inability to tolerate MRI
  7. Use of metformin for any other indication
  8. Renal dysfunction (GFR < 60)
  9. Hepatic dysfunction (AST or ALT > 1.5 x upper limit of normal)
  10. B12 deficiency
  11. Prior poor reaction to metformin
  12. Congestive heart failure
  13. Alcohol abuse
  14. Metabolic acidosis
  15. Females who are pregnant or who plan to become pregnant during the 12 months of enrollment, or who wish to breastfeed during any part of the 12 months of enrollment
  16. Concomitant use of drugs with drug-drug interactions with metformin
  17. Previous adverse effect with metformin treatment

Study details

Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis

NCT05349474

University of California, Los Angeles

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.